This inventor holds 1 USPTO granted patent. Top assignee: Atea Pharmaceuticals, Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Bruno Canard: Innovator in SARS-CoV-2 Therapy
Introduction
Bruno Canard is a notable inventor recognized for his contributions to the field of pharmaceutical innovations. He is currently associated with Atea Pharmaceuticals, Inc., where he focuses on developing therapies for viral infections.
Latest Patents
Bruno Canard holds a patent for "NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY." This patent represents a significant advancement in the treatment of COVID-19, particularly targeting mutant strains of the virus. His innovative approach aims to enhance therapeutic options available for patients.
Career Highlights
Throughout his career, Bruno Canard has demonstrated a commitment to advancing medical science. His work at Atea Pharmaceuticals, Inc. has positioned him as a key player in the fight against viral diseases. With a focus on research and development, he continues to contribute to the pharmaceutical landscape.
Collaborations
Bruno Canard has collaborated with esteemed colleagues such as Jean-Pierre Sommadossi and Kai Lin. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Bruno Canard's work exemplifies the spirit of innovation in the pharmaceutical industry. His contributions, particularly in the realm of SARS-CoV-2 therapy, highlight the importance of research and collaboration in addressing global health challenges.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile